Can I read Fusion Protein Technologies for Biopharmaceuticals (Applications and Challenges) on EtoBox?

Fusion Protein Technologies for Biopharmaceuticals (Applications and Challenges) by Schmidt, Stefan R. is a scholarly article available to read on EtoBox.

What is Fusion Protein Technologies for Biopharmaceuticals (Applications and Challenges) about?

The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugswith Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs. The book covers the major types of fusion proteinsreceptor-traps, immunotoxi

Author

Schmidt, Stefan R.

Publisher

John Wiley & Sons, Incorporated

Published

2013

Language

EN

ISBN

9780470646274